O11 Activated leukocyte cell adhesion molecule (ALCAM/CD166) is an important clinical and prognostic indicator in pancreatic cancer

Abstract Introduction Activated leukocyte cell adhesion molecule (ALCAM/CD166) is a and one of the potential metastasis ‘soil’ receptors that via homotypic heterotypic interactions, mediates adhesion. The present study investigated clinical, pathological prognostic value ALCAM in patients with pancreatic cancer. Method Pancreatic cancer tissues (n = 223), collected immediately after surgery, were analysed for levels transcripts. expression was against clinical outcome patients. We validated our findings an available TCGA database 117), including correlations interactive partners. Result had significantly higher transcript than normal (P < 0.00001). There no significant differences staging, differentiation tumour locations. Tumours from who died high compared those lived 0.018), finding also supported by ROC analysis 0.016). Multivariant showed as independent prognosis factor overall survival (hazardous ratio 5.485), both nodal status TNM staging contributing to model (HR 2.578 3.02 respectively). A surprising relationship between microvessel embolism cells 0.021, vs without embolism). correlated its protein partners CD6 ITGB1, but not L1CAM. Conclusion ALCAM/CD166 aberrant raised cells. Take-home Message indicator